Benefiber ‘Helps Maintain Regularity’ Claim Fails NAD Review; Decision Appealed
This article was originally published in The Tan Sheet
Novartis Health disagrees with the National Advertising Division decision that the Benefiber express claim “helps maintain regulatory” is not supported by research and will appeal the decision. NAD reviewed the claim made in a challenge by Metamucil fiber supplement marketer P&G.
You may also be interested in...
NAD says direct advertising claims for the Neurocet supplement rely on insufficient or ill-fitted research – including summaries – and marketer National Media Group should discontinue numerous statements challenged by the Council for Responsible Nutrition.
“We ought to deal with this. There are questions on long-term safety and questions on efficacy claims that are just not proven,” says the Maryland Republican. “The biggest threat hanging over, in my mind, the farmers who want to grow hemp, is what if the FDA comes out tomorrow and says, ‘You can't sell any product’? The market collapses,”he said at a CBD policy conference.
Minnesota Democrat Collin Peterson’s bill, the first targeting FDA’s CBD question, could provide an entire answer or it could set table for discussion in Congress about legislation on establishing an FDA regulation on using CBD, and potentially other hemp-derived substances, in products other than drugs subject to its oversight.